+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Apomorphine"

From
From
Parkinson's disease - Pipeline Insight, 2024 - Product Thumbnail Image

Parkinson's disease - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 230 Pages
  • Global
From
KYNMOBI Market Size, Forecast, and Market Insight - 2032 - Product Thumbnail Image

KYNMOBI Market Size, Forecast, and Market Insight - 2032

  • Report
  • March 2024
  • 30 Pages
  • Global
From
From
From
From
From
Plumb's Veterinary Drug Handbook. Edition No. 10 - Product Thumbnail Image

Plumb's Veterinary Drug Handbook. Edition No. 10

  • Book
  • July 2023
  • 1568 Pages
  • 10 Results (Page 1 of 1)
Loading Indicator

Apomorphine is a drug used to treat Parkinson's disease and other central nervous system disorders. It is a dopamine agonist, meaning it stimulates dopamine receptors in the brain, which helps to reduce the symptoms of Parkinson's disease. Apomorphine is administered as an injection or infusion, and is available in both oral and sublingual forms. It is also used to treat drug-induced Parkinsonism, a condition caused by certain medications. Apomorphine is a relatively new drug, and its use is still being studied. It is generally considered to be a safe and effective treatment for Parkinson's disease, although it can cause side effects such as nausea, vomiting, and dizziness. The apomorphine market is growing, as more people are being diagnosed with Parkinson's disease and other central nervous system disorders. The market is expected to continue to grow as new treatments are developed and more people are diagnosed with these conditions. Some companies in the apomorphine market include Merck, Novartis, and Teva Pharmaceuticals. Show Less Read more